Enveda Biosciences raised $311M in a funding round that valued the AI-driven biotech company at $2 billion. The company is developing nature-derived drugs using AI, with clinical candidates targeting skin conditions and weight preservation after GLP-1 therapy cessation.
Background
AI-driven drug discovery has emerged as a major trend in biotech, with natural product sourcing combined with AI screening representing a growing niche for novel therapeutics.
- Source
- TechCrunch
- Published
- Sep 24, 2026 at 03:31 AM
- Score
- 6.0 / 10